Eli Lilly and Company announced that data from studies of Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) Bruton tyrosine kinase (BTK) inhibitor, will be presented at the… read more.
Rigel Pharmaceuticals Inc. announced a peer-reviewed publication in the Journal of Hematology & Oncology of the final five-year data from the pivotal cohort of the Phase II registrational… read more.
Eli Lilly and Company announced that new data from across its breast oncology portfolio and pipeline will be featured at the San Antonio Breast Cancer Symposium (SABCS), taking… read more.
Summary Positive results from ianalumab pivotal Phase III trial in ITP patients previously treated with corticosteroids to be presented as late-breaker Scemblix data across clinical and real-world settings… read more.
Ono Pharmaceutical Co., Ltd. announced that they received supplemental approval in Japan for Braftovi (encorafenib) capsule in combination with cetuximab, an anti-human EGFR monoclonal antibody, and chemotherapy for… read more.
Gilead Sciences Inc. announced the Phase III ASCENT-07 study investigating Trodelvy (sacituzumab govitecan-hziy) versus chemotherapy as a first-line treatment post-endocrine therapy in HR+/HER2-negative metastatic breast cancer patients did… read more.
UCLA research finds that fewer than 1 in 4 eligible younger adults completed colorectal cancer screenings after the United States Preventive Services Task Force (USPSTF) lowered the recommended… read more.
Patients with colon cancer who are using glucagon-like peptide-1 (GLP-1) receptor agonists for blood sugar regulation and/or weight control appear to have achieved a significantly lower risk of… read more.
Roche announced that it will showcase 46 abstracts, including 12 oral presentations, from its industry-leading haematology portfolio at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition,… read more.
Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that new data on mitapivat, an oral pyruvate… read more.
Exicure, Inc, a clinical-stage biotechnology company developing therapeutics for hematologic diseases announced that results from its completed Phase 2 study evaluating burixafor, a small molecule CXCR4 antagonist, will… read more.
Rigel Pharmaceuticals, Inc. a commercial stage biotechnology company focused on hematologic disorders and cancer, announced that data from the ongoing Phase 1b study of R2891, a potent and… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
